CARA Treatment Pilot Study for Breast Positioning

Breast Cancer Clinical Trial

Official title:

CARA Treatment Pilot Study for Breast Positioning

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04543851
• Other study ID #: H18-02014
• Status: Completed
• Phase: N/A
• Start date: October 8, 2018
• Est. completion date: November 18, 2019

Study information

• Verified date: September 2020
• Source: British Columbia Cancer Agency
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CARA is a novel Carbon-fibre Adjustable and Re-usable Accessory for supine breast positioning during radiation therapy. CARA was developed at BC Cancer. In this study, twenty patients will be planned and treated with CARA positioning to establish safety and workflow measures of this novel device. The device is designed to remove the infra-mammary skin fold and lateral breast droop which can lead to unwanted dose to normal tissue.

Description:

This pilot study will investigate the safety and potential benefits of CARA breast positioning by treating 20 patients using the device. Patients will be planned with CARA positioning and standard of care positioning. CARA plans will be evaluated to ensure all treatment planning goals are met and patients will proceed to treatment with CARA positioning. This pilot study will ensure that patients can be safely treated with the CARA and provide us with valuable information from therapists, oncologists and patients about the performance of the current design. This will also inform the direction of design improvements and the production of educational materials for training practitioners in the use of the device. Overall, this will prepare us for a randomized clinical trial of the CARA positioning technique versus current standard of practice to assess whether reduced toxicity can be achieved using the CARA technique.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 18, 2019
• Est. primary completion date: November 4, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

Patients diagnosed with completely excised stage I or II invasive breast cancer, or ductal carcinoma in situ (DCIS), who have undergone breast-conserving surgery and are scheduled to undergo adjuvant breast radiotherapy;

Any breast size with a skin fold of depth 1 cm or greater at the infra-mammary crease at the time of radiation treatment planning, or brassiere cup size equal to or larger than D;

Patients undergoing nodal radiotherapy are eligible if the above criteria are met;

Patients undergoing boost radiotherapy are eligible if the above criteria are met, but only if the surgical scar does not extend inferior to the nipple line of the breast;

Language is not a barrier if there are interpreters/family members to translate;

Patients having had chemotherapy are eligible for this study;

Exclusion Criteria:

Inability to give informed consent or comply with requirements of the trial;

Failure of healing of the surgical scar or significant post-operative wound infection;

Prior radiotherapy to either breast or to the chest;

Presence of significant connective tissue disease (e.g. systemic sclerosis); known radiation hypersensitivity phenotype (e.g. ataxia telangiectasia);

Inability to return for assessment at both one week and two weeks following completion of radiotherapy;

Breast reconstruction;

Use of Mepitel® wound dressing product.

Related Conditions & MeSH terms

• Breast Cancer
• Side Effect

Intervention

Device:
• CARA - carbon fibre adjustable re-usable accessory for breast positioning
Breast positioning to alleviate infra-mammary fold and lateral breast sag

Locations

Country	Name	City	State
Canada	BC Cancer	Vancouver	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
British Columbia Cancer Agency	Canadian Cancer Society Research Institute (CCSRI)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants for whom dose volume treatment planning constraints are not met using CARA support for breast setup	Treatment planning dose constraints are: >=95% of the prescribed dose covering >=98% of the breast target tissue, including internal mammary chain when requested by the treating oncologist; volume of ipsi-lateral lung receiving >= 20Gy should be <=35%; volume of heart receiving >=25Gy should be <=5%; maximum dose to any point in the body <=110% of the prescribed dose; volume of breast receiving >=107% of prescribed dose should be <=22 cm^3	12 months
Primary	Number of participants having measured breast skin dose => 110% of the prescribed dose to an area of skin => 1 cm^2	Skin dose is measured on the breast surface under the carbon fibre device using radio-chromic film. The area of skin receiving 70% of the prescribed dose up to the maximum absorbed dose is measured in 5% dose increments to an accuracy of 0.5 cm^2.; If any participant receives => 110% of the prescribed dose to >=1 cm^2 area of skin, the study will be stopped.	12 months
Primary	Number of participants scoring =>6 on the CTCAE Version 4.0 skin assessment	Participants will undergo a detailed breast skin assessment at baseline, one week prior to RT completion, last week of RT, and one and two weeks post RT using the CTCAE Version 4 skin assessment scoring system as well as examination of the infra-mammary fold for any moist desquamation. The dimensions and location of moist desquamation will be recorded. In the event that a skin reaction of = 6 (indicating ulceration, hemorrhage or necrosis) on the CTCAE V 4.0 scale is reported, the trial will be stopped.	12 months
Secondary	Workflow measures	Measured time to accomplish set up and treatment with CARA positioning	12 months
Secondary	Setup reproducability	Measure required shifts in patient position using kilo-voltage imaging	12 months
Secondary	Doses to organs at risk comparison with standard of care	Comparison of lung, heart, breast and normal tissue dose versus standard of care	12 months
Secondary	Skin assessment versus skin dose	CTCAE V4 and specific moist desquamation assessment of breast skin compared with measured skin dose-area data	12 months
Secondary	Patient Reported outcome - skin reaction	Questionnaire to assess patient reported side effects and skin reaction	12 months